NCT00698334View on ClinicalTrials.gov

Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

April 30, 2011

Conditions
HIV InfectionsAcquired Immunodeficiency SyndromeTuberculosis
Interventions
DRUG

INH, Rifampicin, Ethambutol and Pyrazinamide

Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)

DRUG

INH, Rifampicin, Ethambutol and Pyrazinamide

Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)

Trial Locations (1)

110029

All India Institute of Medcial Sciences, New Delhi

All Listed Sponsors
collaborator

Ministry of Health & Family Welfare, India

OTHER_GOV

lead

All India Institute of Medical Sciences

OTHER

NCT00698334 - Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis | Biotech Hunter | Biotech Hunter